CNTX
Context Therapeutics Inc
NASDAQ: CNTX · HEALTHCARE · BIOTECHNOLOGY
$2.34
-6.77% today
Updated 2026-04-29
Market cap
$207.65M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.38
Dividend yield
—
52W range
$0 – $4
Volume
0.9M
Context Therapeutics Inc (CNTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | $0.00 | $0.00 | — | — | — | $9268.00 | $12044.00 | $52703.00 | $124657.00 |
| Gross profit | $0.00 | $0.00 | — | — | — | $-9268.00 | $-12044.00 | $-52703.00 | $-124657.00 |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $27.79M | $17.62M | $2.41M | $1.64M | $3.81M | $7.09M | $17.78M | $22.70M | $31.86M |
| SG&A | $33.20M | $24.03M | $2.97M | $930667.00 | $3.63M | $7.79M | $7.29M | $7.22M | $7.85M |
| Operating income | $-33.23M | $-24.05M | $-5.38M | $-2.57M | $-10.53M | $-15.38M | $-25.07M | $-29.92M | $-39.70M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | — | — | $-5.38M | $-2.57M | $-10.39M | $-14.87M | $-25.06M | $-29.91M | $-39.70M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-33.23M | $-24.05M | $-5.38M | $-2.57M | $-7.44M | $-14.88M | $-25.07M | $-29.92M | — |
| Interest expense | $0.00 | $0.00 | $1.10M | $661224.00 | $64240.00 | $547268.00 | — | — | — |
| Income tax | $0.00 | $-441000.00 | $1.10M | $661224.00 | $-3.02M | $-545000.00 | $-4.00 | — | — |
| Effective tax rate | 0.0% | 1.8% | -17.2% | 9.1% | 22.4% | 3.5% | 0.0% | 0.0% | 0.0% |
| Net income | $-37.67M | $-24.61M | $-7.48M | $6.64M | $-10.46M | $-14.84M | $-23.96M | $-26.73M | $-36.12M |
| Net income growth (YoY) | — | +34.7% | +69.6% | +188.8% | -257.4% | -41.9% | -61.5% | -11.5% | -35.2% |
| Profit margin | — | — | — | — | — | — | — | — | — |